Published in Ann Surg Oncol on July 01, 2002
Retroperitoneal sarcomas. Cancer Imaging (2005) 1.09
Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities. Radiat Oncol (2011) 0.97
Major vascular resection and prosthetic replacement for retroperitoneal tumors. World J Surg (2006) 0.90
Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol (2007) 0.84
Radiation-sparing managements for cervical cancer: a developing countries perspective. World J Surg Oncol (2006) 0.83
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer (2015) 0.76
Neoadjuvant chemoradiation therapy for soft tissue sarcomas of the extremities. Clinics (Sao Paulo) (2009) 0.75
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. Am J Clin Oncol (2016) 0.75
We should desist using RECIST, at least in GIST. J Clin Oncol (2007) 4.51
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer (2003) 2.64
Mortality after cure of testicular seminoma. J Clin Oncol (2004) 2.53
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
Angiosarcoma of the breast. Cancer (2005) 1.98
Gastrointestinal stromal tumors: current management. J Surg Oncol (2010) 1.75
Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck (2007) 1.73
Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer (2002) 1.67
Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys (2003) 1.57
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer (2010) 1.53
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer (2011) 1.50
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg (2003) 1.45
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol (2009) 1.38
Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.30
Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer (2004) 1.30
Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol (2005) 1.25
A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer (2003) 1.24
Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer (2003) 1.24
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res (2010) 1.23
Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer (2007) 1.21
Liposarcoma of the head and neck: The University of Texas M. D. Anderson Cancer Center experience. Head Neck (2009) 1.18
Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer (2006) 1.17
Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer (2006) 1.15
Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.13
Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys (2006) 1.10
Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys (2003) 1.06
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer (2002) 1.06
Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.06
Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.05
Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol (2003) 1.04
The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol (2006) 1.02
The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer (2009) 1.02
The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res (2013) 0.99
Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg (2007) 0.98
Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas. Cancer (2002) 0.95
Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck (2008) 0.95
Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys (2003) 0.93
On the feasibility of treating to a 1.5 cm PTV with a commercial single-entry hybrid applicator in APBI breast brachytherapy. J Contemp Brachytherapy (2012) 0.90
Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol (2004) 0.88
Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib. Curr Oncol Rep (2002) 0.88
Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. Int J Radiat Oncol Biol Phys (2007) 0.87
Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys (2004) 0.84
Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer (2006) 0.84
Sequencing radiotherapy for soft tissue sarcoma when re-resection is planned. Int J Radiat Oncol Biol Phys (2003) 0.83
Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer (2004) 0.83
Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. Ophthal Plast Reconstr Surg (2008) 0.81
A new paradigm for calculating skin dose. Brachytherapy (2012) 0.81
Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res (2009) 0.81
Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep (2005) 0.81
Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys (2008) 0.80
Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy. Cancer (2008) 0.79
Malignant fibrous histiocytoma of the head and neck region. Head Neck (2011) 0.78
Staged reconstruction for resection wounds in sarcoma patients treated with brachytherapy. Ann Plast Surg (2008) 0.77
Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res (2012) 0.76
Classification of clear-cell sarcoma. Curr Oncol Rep (2004) 0.75
The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators. Radiother Oncol (2006) 0.75
Functional outcome after treatment of lower extremity soft tissue sarcoma: what should we tell our patients? Ann Surg Oncol (2004) 0.75
Molecular testing for synovial sarcoma. Curr Oncol Rep (2004) 0.75
Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors. Curr Oncol Rep (2003) 0.75
Periosteal margin in soft-tissue sarcoma. Cancer (2007) 0.75
Benign Tumors of the Spine: Has New Chemotherapy and Interventional Radiology Changed the Treatment Paradigm? Spine (Phila Pa 1976) (2016) 0.75
Recent studies in novel therapy for metastatic sarcomas. Hematol Oncol Clin North Am (2005) 0.75
Clinical Decision Making: Integrating Advances in the Molecular Understanding of Spine Tumors. Spine (Phila Pa 1976) (2016) 0.75
Clinical update on adult and pediatric gastrointestinal stromal tumor. Preface. Hematol Oncol Clin North Am (2009) 0.75